Last reviewed · How we verify
IDE196
Selective inhibitor of MEK1/2
Selective inhibitor of MEK1/2 Used for Non-small cell lung cancer, Colorectal cancer.
At a glance
| Generic name | IDE196 |
|---|---|
| Also known as | Darovasertib, Protein Kinase C (PKC) Inhibitor |
| Sponsor | IDEAYA Biosciences |
| Drug class | MEK inhibitor |
| Target | MEK1/2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
IDE196 is a potent and selective inhibitor of MEK1/2, which are key regulators of the MAPK signaling pathway. Inhibition of MEK1/2 has been shown to be effective in treating various cancers.
Approved indications
- Non-small cell lung cancer
- Colorectal cancer
Common side effects
- Diarrhea
- Nausea
- Vomiting
Key clinical trials
- (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma (PHASE2)
- Neoadjuvant Darovasertib in Primary Uveal Melanoma (PHASE3)
- IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma (PHASE2, PHASE3)
- Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IDE196 CI brief — competitive landscape report
- IDE196 updates RSS · CI watch RSS
- IDEAYA Biosciences portfolio CI